J&J on go with early-stage study of COVID-19 vaccine candidate

In an interview on CNBC’s Squawk Box, Johnson & Johnson (NYSE:JNJ) EVP and CFO Joseph Wolk stated that the company’s 1,000-subject Phase 1 clinical trial evaluating its COVID-19 vaccine candidate Ad26.COV2-S should start next week.

If all goes well, a Phase 3 will launch in September.

https://seekingalpha.com/news/3591841-j-and-j-on-go-early-stage-study-of-covidminus-19-vaccine-candidate